Cridanimod, also known as cycloferon or meglumine acridone acetate,[1] is a low molecular weight immunomodulatory drug known for its ability to induce the production of interferons, which are proteins that play a crucial role in the immune response against viral infections.

By stimulating the production of these interferons, cridanimod enhances the immune system's ability to combat viral infections and reduce the severity and duration of symptoms.

In the context of respiratory infections, cridanimod has been shown to significantly reduce the duration and intensity of symptoms such as fever and to decrease the incidence of complications like pneumonia.

[4] In a systematic review and meta-analysis, cridanimod was found to increase the chances of recovery and reduce the frequency of recurrent exacerbations in otorhinolaryngologic diseases by 25%.

Studies indicate that cycloferon can provide more than a three-fold increase in achieving stable remission and reducing exacerbation frequency compared to basic therapies.